[1] DOUROS J, 曹玉泉. 美国抗癌研究所对美登木素的研究[J]. 国外药学(植物药分册), 1981(5):9-14. DOUROS J, CAO Yuquan. American institute for cancer research on maytansinc[J]. Foreign Pharmacy (Plant Sciences), 1981(5):9-14.
[2] RINEHART K L, SHIELD L S. Chemistry of the ansamycin antibiotics[M]. Vienna:Springer, 1976:231-307.
[3] ASAI M, MIZUTA E, IZAWA M, et al. Isolation, chemical characterization and structure of ansamitocin, a new antitumor ansamycin antibiotic[J]. Tetrahedron, 1979, 35(9):1079-1085.
[4] JOHN M C, KENNETH K C, HEINZ G F, et al. Recent developments in the maytansinoid antitumor agents[J]. Chem. Pharm. Bull., 2004, 52(1):1-26.
[5] HIGASHIDE E, ASAI M, OOTSU K, et al. Ansamitocin, a group of novel maytansinoid antibiotics with antitumor properties from Nocardia[J]. Nature, 1977, 270:721-722.
[6] STEPHEN C A, NICOLE M O, PETER D S. Antibody-drug conjugates:targeted drug delivery for cancer[J]. Curr. Opin. Chem. Biol., 2010, 14:529-537.
[7] TANIDA S, HASEGAWA T, HATANO K, et al. Ansamitocins, maytansinoid antitumor antibiotics producing organism, fermentation, and antimicrobial activities[J]. J. Antibiot., 1980, 33(2):192-198.
[8] HAJJAJ H, NIEDERBERGER P, DUBOC P. Lovastatin biosynthesis by Aspergillus terreus in a chemically defined medium[J]. Appl. Environ. Microbiol., 2001, 67:2596-2602.
[9] LOPUS M. Antibody-DM1 conjugates as cancer therapeutics[J]. Cancer. Lett., 2011, 307(2):113-118.
[10] HOWARD A, BURRIS Ⅲ, HOPE S RUGO, et al. Phase Ⅱ study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2(HER2) -positive breast cancer after prior HER2-directed therapy[J]. J. Clin. Oncol., 2011, 29(4):398-405.
[11] WAKANKAR A A, FEENEY M B, RIVERA J, et al. Physicochemical stability of the antibody-drug conjugate trastuzumab-DM1:changes due to modification and conjugation processes[J]. Bioconjug. Chem., 2010, 21(9):1588-1595.
[12] POLSON A G, WILLIAMS M, GRAYA M, et al. Anti-CD22-MCC-DM1:an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma[J]. Leukemia, 2010, 24(9):1566-1573.
[13] JUMBE N L, XIN Y, LEIPOLD D D, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice[J]. J. Pharm. Pharmacol., 2010, 37(3):221-242.
[14] KROP I E, BEERAM M, MODI S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer[J]. J. Clin. Oncol., 2010, 28(16):2698-2704.
[15] LEWIS PHILLIPS G D, LI G, DUGGER D L, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate[J]. Cancer Research, 2008, 68(22):9280-9290.
[16] LIU Z F, FLOSS H G, CASSADY J M, et al. Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry[J]. J. Mass Spectrom., 2005, 40:389-399.
[17] FAN Y X, HU F X, WEI L J, et al. Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum[J]. J. Biochem., 2016, 230:3-10.
[18] FAN Y X, ZHAO M J, WEI L J, et al. Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum[J]. Appl. Microbiol. Biotechnol., 2016, 100:2651-2662.
[19] ZHAO M J, FAN Y X, WEI L J, et al. Effects of the methylmalonyl-CoA metabolic pathway on ansamitocin production in Actinosynnema pretiosum[J]. Appl. Biochem. Biotechnol., 2017, 181:1167-1178.
[20] ZHAO P J, BAI L Q, MA J, et al. Amide N-glycosylation by asm25, an N-glycosyltransferase of ansamitocin[J]. Chem. Biol., 2008, 15:863-874.
[21] LU C H, BAI L Q, SHEN Y M. Five unusual natural carbohydrates from Actinosynnema pretiosum[J]. Chem. Nat. Compd., 2008, 44:594-597.
[22] WEI G Z, BAI L Q, YANG T, et al. A new antitumour ansamitocin from Actinosynnema pretiosum[J]. Nat. Pro. Res., 2010, 24:1146-1150.
[23] 伊丹, 王岩, 陈少欣. 安丝菌素P-3的发酵工艺[J]. 中国医药工业杂志, 2012, 43(4):260-262. YI D, WANG Y, CHEN S X.Fermentation process for the production of ansamitocin P-3[J].Chinese Journal of Phamaceuticals, 2012, 43(4):260-262.
[24] SPITELLER P, BAI L Q, SHANG G D, et al. The post-polyketide synthetase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum[J]. J. Am. Chem. Soc., 2003, 125:14236-14237.
[25] 李婷兰, 韦柳静, 范宇翔, 等. 奇迹束丝放线菌合成安丝菌素过程中支链氨基酸的添加效果分析[J]. 华东理工大学学报, 2013, 39(6):675-680. LI T L, WEI L J, FAN Y X, et al.Effects analysis of adding branched amino acids on the biosynthesis of ansamitocins by actinosynnema minim[J]. Journal of East China University of Science and Technology, 2013, 39(6):675-680.
[26] 罗洋, 滕应, 刘方, 等. 里氏木霉FS10-C固体发酵基质筛选及发酵条件初探[J]. 生物技术通报, 2014, 3:111-116. LUO Y, TENG Y, LIU F, et al.Screening of solid media and optimization of the fermentation conditions for trichoderma reesei FS10[J]. Biotechnology Bulletin, 2014, 3:111-116.
[27] DOMí NGUEZ M, MEJí A A, REVAH S, et al. Optimization of bagasse, nutrients and initial moisture ratios on the yield of penicillin in solid state fermentation[J]. World J. Microbiol. Biotechnol., 2001, 17(7):751-756.
[28] 谷政伟, 朱晓媛, 黎继烈. 安丝菌素P-3的摇瓶发酵培养基优化[J]. 湖北农业科学, 2015, 54(11):2707-2714. GU Z W, ZHU X Y, LI J H.Optimization of shaking-flask fermentation medium for ansamitocin P-3[J].Hubei Agricultural Sciences, 2015, 54(11) 2707-2714.
[29] BALAKRISHNAN K, PANDEY A. Production of biologically active secondary metabolites in solid state fermentation[J]. J. Sci. Ind. Res., 1996, 55(2):365-372.
[30] SEKA R C, RAJASEKAR V W, BALA RAMAN K. Production of cyclosporine A by solid state fermentation[J]. Bioprocess. Eng., 1997, 17(4):257-259.
[31] OHNO A, ANO T, SHODA M. Use of soybean curd residue, Okara, for the solid state substrate in the production of a lipopeptide antibiotic, iturin A, by Bacillus subtilis NB22[J]. Proc. Bio. Chem., 1996, 31(8):801-806. |